<DOC>
	<DOCNO>NCT01039519</DOCNO>
	<brief_summary>The purpose study determine STA-9090 effective treatment patient metastatic and/or unresectable GIST .</brief_summary>
	<brief_title>A Study Evaluating STA-9090 Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor ( GIST )</brief_title>
	<detailed_description>Planned : - Stage 1 : 23 patient . If â‰¥4 patient clinical benefit , additional 32 patient enrol . Up 3 additional patient platelet-derived growth factor receptor , alpha polypeptide ( PDGFRA ) mutation enrol , regardless total study enrollment . - Stage 2 : 55 patient . Progressing stage dependent Stage 1 result . Analyzed : - Stage 1 : 27 patient enrol analyze . The study expand Stage 2 due insufficient efficacy .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Must least 18 year age time study entry Must histologically confirm metastatic and/or unresectable GIST Must measurable disease compute tomography magnetic resonance imaging define Response Evaluation Criteria Solid Tumors ( RECIST ) Must document failure ( due either progression intolerance ) least prior imatinib sunitinib . Previous administration know heat shock protein 90 ( Hsp90 ) inhibitor permit Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Must acceptable laboratory value define protocol Known central nervous system metastases Major surgery within 4 week prior receive STA9090 Use investigational agent within 2 week 6 halflives agent , whichever short prior receive STA9090 No treatment chronic immunosuppressant Must otherwise adequate health status define protocol Left ventricular ejection fraction ( LVEF ) &lt; = 50 % baseline Baseline correct QT interval ( QTc ) &gt; 470 msec Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>G.I . Stromal Tumor</keyword>
	<keyword>GIST</keyword>
</DOC>